TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort

被引：1
|
作者：
Yuan, J. [1 ]
Zheng, Y. [2 ]
Xu, L. [3 ]
Xie, F. [4 ]
Gu, S. [5 ]
Li, Q. [6 ]
Zhang, J. [7 ]
Ba, Y. [8 ]
Huaxin, D. [9 ]
Yang, A. [10 ]
Li, J. [10 ]
Zhou, J. [11 ]
Shen, L. [11 ]
机构：
[1] Peking Univ, Dept Gastrointestinal Oncol, Canc Hosp Inst, Beijing, Peoples R China
[2] Zhejiang Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[4] Chinese PLA Naval Mil Med Univ, Dept Surg, Affiliated Hosp 3, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Intervent Div, Changsha, Peoples R China
[6] SCU Sichuan Univ, Dept Oncol, Huaxi Campus, Chengdu, Peoples R China
[7] Southern Med Univ, Dept Oncol, ZhuJiang Hosp, Zhujiang, Peoples R China
[8] Tianjin Med Univ, Dept Gastroenterol, Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hunan Prov Peoples Hosp, Dept Oncol, Changsha, Peoples R China
[10] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Clin Med, Lianyungang, Peoples R China
[11] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [41] Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma
    Tap, William D.
    Cote, Gregory Michael
    Burris, Howard A.
    Gore, Lia
    Beeram, Muralidhar
    Conley, Anthony Paul
    Gianolio, Diego A.
    Qu, Zhe
    Gliser, Camelia
    Pandya, Shuchi Sumant
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
    Tsai, Hui-Jen
    Shiah, Her-Shyong
    Chang, Jang-Yang
    Su, Wu-Chou
    Chiang, Nai-Jung
    Chen, Li-Tzong
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
    Hui-Jen Tsai
    Her-Shyong Shiah
    Jang-Yang Chang
    Wu-Chou Su
    Nai-Jung Chiang
    Li-Tzong Chen
    Scientific Reports, 11
  • [44] A phase I dose escalation and cohort expansion study of T-cell redirecting bispecific antibody against Glypican 3 in patients with advanced solid tumors
    Hashimoto, Kenji
    Perera, Ayesh
    Ogita, Yoshitaka
    Nakamura, Mikiko
    Ishiguro, Takahiro
    Sano, Yuji
    Kinoshita, Yasuko
    Sakurai, Mika Kamata
    Frings, Werner
    Komatsu, Shun-ichiro
    Kaneko, Akihisa
    Ueda, Masamichi
    Kishishita, Shohei
    Gianella-Borradori, Athos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
    Heuser, Michael
    Palmisiano, Neil
    Mantzaris, Ioannis
    Mims, Alice
    DiNardo, Courtney
    Silverman, Lewis R.
    Wang, Eunice S.
    Fiedler, Walter
    Baldus, Claudia
    Schwind, Sebastian
    Pardee, Timothy
    Perl, Alexander E.
    Cai, Charles
    Kaulfuss, Stefan
    Lagkadinou, Eleni
    Rentzsch, Christine
    Wagner, Markus
    Wilkinson, Gary
    Wu, Bingyan
    Jeffers, Michael
    Genvresse, Isabelle
    Kraemer, Alwin
    LEUKEMIA, 2020, 34 (11) : 2903 - 2913
  • [46] Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
    Michael Heuser
    Neil Palmisiano
    Ioannis Mantzaris
    Alice Mims
    Courtney DiNardo
    Lewis R. Silverman
    Eunice S. Wang
    Walter Fiedler
    Claudia Baldus
    Sebastian Schwind
    Timothy Pardee
    Alexander E. Perl
    Charles Cai
    Stefan Kaulfuss
    Eleni Lagkadinou
    Christine Rentzsch
    Markus Wagner
    Gary Wilkinson
    Bingyan Wu
    Michael Jeffers
    Isabelle Genvresse
    Alwin Krämer
    Leukemia, 2020, 34 : 2903 - 2913
  • [47] Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
    Milan G. Chheda
    Patrick Y. Wen
    Fred H. Hochberg
    Andrew S. Chi
    Jan Drappatz
    April F. Eichler
    Daniel Yang
    Rameen Beroukhim
    Andrew D. Norden
    Elizabeth R. Gerstner
    Rebecca A. Betensky
    Tracy T. Batchelor
    Journal of Neuro-Oncology, 2015, 121 : 627 - 634
  • [48] Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study
    Chheda, Milan G.
    Wen, Patrick Y.
    Hochberg, Fred H.
    Chi, Andrew S.
    Drappatz, Jan
    Eichler, April F.
    Yang, Daniel
    Beroukhim, Rameen
    Norden, Andrew D.
    Gerstner, Elizabeth R.
    Betensky, Rebecca A.
    Batchelor, Tracy T.
    JOURNAL OF NEURO-ONCOLOGY, 2015, 121 (03) : 627 - 634
  • [49] Updated analysis of phase I dose-escalation and dose cohort expansion studies of senaparib (IMP4297) in Chinese patients with advanced solid tumours
    Xu, B.
    Junning, C.
    Guo, H.
    Zhang, P.
    Yang, S.
    Zhou, Y.
    Zhang, R.
    Dongmei, J.
    Shen, W.
    Zhang, S.
    Cai, S.
    Tian, Y. E.
    Hsieh, C-Y.
    Xu, C.
    Ma, N.
    Chen, Y.
    Yang, S.
    Zhang, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S491 - S491
  • [50] Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
    Coombes, R. Charles
    Howell, Sacha
    Lord, Simon R.
    Kenny, Laura
    Mansi, Janine
    Mitri, Zahi
    Palmieri, Carlo
    Chap, Linnea I.
    Richards, Paul
    Gradishar, William
    Sardesai, Sagar
    Melear, Jason
    O'Shaughnessy, Joyce
    Ward, Patrick
    Chalasani, Pavani
    Arkenau, Tobias
    Baird, Richard D.
    Jeselsohn, Rinath
    Ali, Simak
    Clack, Glen
    Bahl, Ashwani
    McIntosh, Stuart
    Krebs, Matthew G.
    NATURE COMMUNICATIONS, 2023, 14 (01)
12345